CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Swiss biotech firm Molecular Partners to cut nearly half of workforce

By Reuters News

ZURICH, Oct 29 (Reuters) - Switzerland's Molecular Partners MOLN.S is cutting its workforce nearly in half, it said on Thursday, as it aims to narrow its focus on the booming field of radiotherapeutic medicines.

The clinical-stage biotech company, which has partnered with pharma giant Novartis NOVN.S and American AbbVie ABBV.N, is set to reduce its employee headcount by up to 44%, or up to 55 people.

  • Emerging clinical data for its lead radiotherapeutic drug candidate encouraged company transformation with focus on targeted radiotherapy, CEO Patrick Amstutz said in a statement

  • The reduction is expected be completed by the second quarter of 2027 and the related costs set to come into effect in the second half of the same year, Molecular Partners said

  • Previously announced timelines on clinical assets stand, the company said

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.